CA2067374A1 - Promoteur de l'osteogenese - Google Patents

Promoteur de l'osteogenese

Info

Publication number
CA2067374A1
CA2067374A1 CA2067374A CA2067374A CA2067374A1 CA 2067374 A1 CA2067374 A1 CA 2067374A1 CA 2067374 A CA2067374 A CA 2067374A CA 2067374 A CA2067374 A CA 2067374A CA 2067374 A1 CA2067374 A1 CA 2067374A1
Authority
CA
Canada
Prior art keywords
osteogenesis promoter
osteogenesis
promoter
osateogenesis
carnosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2067374A
Other languages
English (en)
Other versions
CA2067374C (fr
Inventor
Masayoshi Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamari Chemicals Ltd
Zeria Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2067374A1 publication Critical patent/CA2067374A1/fr
Application granted granted Critical
Publication of CA2067374C publication Critical patent/CA2067374C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002067374A 1989-10-02 1990-09-28 Promoteur de l'osteogenese Expired - Fee Related CA2067374C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1255325A JP2811331B2 (ja) 1989-10-02 1989-10-02 骨形成促進剤
JP255325/1989 1989-10-02
PCT/JP1990/001255 WO1991004737A1 (fr) 1989-10-02 1990-09-28 Promoteur d'osteogenese

Publications (2)

Publication Number Publication Date
CA2067374A1 true CA2067374A1 (fr) 1991-04-03
CA2067374C CA2067374C (fr) 2000-07-04

Family

ID=17277215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002067374A Expired - Fee Related CA2067374C (fr) 1989-10-02 1990-09-28 Promoteur de l'osteogenese

Country Status (8)

Country Link
US (1) US5294634A (fr)
EP (1) EP0495106B1 (fr)
JP (1) JP2811331B2 (fr)
KR (1) KR0147855B1 (fr)
AT (1) ATE131047T1 (fr)
CA (1) CA2067374C (fr)
DE (1) DE69024060T2 (fr)
WO (1) WO1991004737A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2811353B2 (ja) * 1990-07-06 1998-10-15 ゼリア新薬工業株式会社 炎症性腸疾患予防・治療剤
US20020150629A1 (en) * 2000-05-31 2002-10-17 Yasuhiro Nishimura Zinc-supplementary compositions for oral administration
RU2552939C2 (ru) 2009-11-25 2015-06-10 Дифьюжн Текнолоджиз, Инк. Пост-загрузка покрытых цеолитом пластиков антимикробными ионами металлов
WO2011072212A2 (fr) 2009-12-11 2011-06-16 Difusion Technologies, Inc. Procédé de fabrication d'implants antimicrobiens en polyétheréthercétone
US8936804B2 (en) 2010-01-15 2015-01-20 Rutgers, The State University Of New Jersey Use of vanadium compounds to accelerate bone healing
EP2571542B1 (fr) 2010-05-07 2018-06-20 Difusion Technologies Inc. Implants médicaux ayant un caractère hydrophile augmenté
EP2648718B1 (fr) 2010-12-10 2019-05-08 Rutgers, the State University of New Jersey Dispositifs implantables revêtus de composites d'agent mimétique de l'insuline, et procédés associés
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
US9931348B2 (en) 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63229058A (ja) * 1987-03-17 1988-09-22 大鳥　泰雅 骨形成材料の製法
JPH0717505B2 (ja) * 1989-02-23 1995-03-01 絹子 永井 骨粗鬆症予防剤

Also Published As

Publication number Publication date
DE69024060T2 (de) 1996-08-01
KR0147855B1 (ko) 1998-08-17
CA2067374C (fr) 2000-07-04
JPH03120257A (ja) 1991-05-22
KR920703050A (ko) 1992-12-17
EP0495106A1 (fr) 1992-07-22
JP2811331B2 (ja) 1998-10-15
US5294634A (en) 1994-03-15
ATE131047T1 (de) 1995-12-15
EP0495106A4 (en) 1992-09-30
WO1991004737A1 (fr) 1991-04-18
DE69024060D1 (de) 1996-01-18
EP0495106B1 (fr) 1995-12-06

Similar Documents

Publication Publication Date Title
CA2031384A1 (fr) Concentres du composant actif et nouvelles combinaisons du composant actif des feuilles de ginkgo biloba, mode de fabrication, et produits pharmaceutiques contenant lesdit
CA2179648A1 (fr) Compositions herbicides sous forme d'une solution d'azote et d'ether de diphenyle et leur procede d'utilisation
EP0598129A4 (en) Novel tetrapeptide derivative.
CA2016659A1 (fr) Compose stabilise contenant un facteur de croissance epidermique
CA2168113A1 (fr) Derives de peptides, agents therapeutiques
CA2009735A1 (fr) Composes nitro actifs comme insecticides
EP0259485A4 (fr) Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens.
CA2116066A1 (fr) Composition stabilisee de troponine pour dosages immunologiques et procede de stabilisation de la troponine pour dosages immunologiques
AU674358B2 (en) Novel 1,2-benzoisoxazole derivative or its salt and brain -protecting agent comprising the same
CA2060104A1 (fr) Compositions solides de glyphosate et leur utilisation
CA2067374A1 (fr) Promoteur de l'osteogenese
CA2217710A1 (fr) Substance anticancereuse inhibant les metastases cancereuses
CA2026990A1 (fr) Agent anti-vih
CA2018791A1 (fr) Compose capillaire
CA2047802A1 (fr) Compositions pharmaceutiques
CA2223619A1 (fr) Sarcosinates utilises comme adjuvants et activateurs de fluazifop-p-butyle
CA2114859A1 (fr) Compose cytotoxique et antiviral
CA2123083A1 (fr) Usages du 1,1,1,3,3,3-hexafluoropropane
CA2041380A1 (fr) Utilisation de la proteine c ou de la proteine c activee pour la preparation d'une composition pharmaceutique
CA2158261A1 (fr) Melange a tartiner a faible teneur en gras
CA2171728A1 (fr) Derives de triarylethylene pour utilisation therapeutique
EG19425A (en) New compound of n-amino-1,2,4- triazinones their use as pesticide.
EP0212729A3 (fr) Procédé de préparation de diesters d'acides alcanedioiques
AU1562492A (en) Substituted salicylamides, agents to combat plant diseases
AU3617489A (en) A peptide with antihypertensive activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed